CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
Published on December 18, 2020
![[htbx_correspatm002.gif]](htbx_correspatm002.gif)
Heat Biologics, Inc.
627 Davis Drive, Suite 400
Morrisville, North Carolina 27560
December 18, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Alan Campbell
|
|
|
|
|
Re: |
Heat Biologics, Inc. |
|
|
|
Registration Statement on Form S-3 |
|
|
|
File No. 333-251255 |
Dear Mr. Campbell:
Heat Biologics, Inc. (the Company) hereby requests that the effective date of the Companys Registration Statement on Form S-3 (File No. 333-251255) be accelerated by the U.S. Securities and Exchange Commission to Tuesday, December 22, 2020 at 5:00 pm, New York City Time, or as soon as reasonably practicable thereafter.
The Company hereby authorizes Leslie Marlow and/or Patrick Egan of Gracin & Marlow, LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457, or Mr. Egan at (914) 557-5574 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
|
|
|
|
|
|
|
|
Very truly yours, | ||
|
|
|
|
|
Heat Biologics, Inc. | ||
|
|
|
|
|
By: |
|
/s/ Jeffrey Wolf |
|
|
|
Name: Jeffrey Wolf |
|
|
|
Title: Chief Executive Officer |
cc: Leslie Marlow, Esq. (Gracin & Marlow, LLP)
Patrick Egan, Esq. (Gracin & Marlow, LLP)